WASHINGTON, July 30, 2018 /PRNewswire/ -- The Antimicrobials
Working Group (AWG) announced today the addition of Summit
Therapeutics plc (NASDAQ: SMMT; AIM: SUMM) (Summit) to its
coalition of companies with the mission to combat drug resistant
infections and spur life-saving innovations. Summit is an
international biopharmaceutical company developing new mechanism
antibiotics for C. difficile infection and gonorrhea and is
using its proprietary Discuva Platform to expand its pipeline.
The new addition brings AWG's membership to 19 antimicrobial
drug and diagnostic device development companies in the United States and Europe.
"Summit Therapeutics is committed to antibiotic innovation, and
is one of several AWG member companies with locations both in
the United States and abroad,"
said Jeffrey Stein, Ph.D., president
and chief executive officer of Cidara Therapeutics and Chairman of
AWG. "Antimicrobial resistance is one of the greatest threats to
public health worldwide, and will require coordinated action by
stakeholders across government, academia and industry to ensure
doctors and patients have a full armamentarium of treatment
options. AWG looks forward to continued collaboration at all levels
to advance legislation and regulatory policies that support
innovation in the treatment of infectious diseases."
"Our AWG membership could allow us to impact important policies
that improve the legislative, regulatory and commercial environment
for antibiotic drug developers, such as ourselves," said Dr.
David Roblin, chief medical officer
and president of R&D of Summit. "We believe our pipeline of new
mechanism antibiotics could benefit from such policies, which will
help to bring much needed new medicines to society."
All pharmaceutical and biotechnology companies developing new
antimicrobial therapeutics and diagnostic devices are eligible for
consideration of membership in AWG. If you are interested in
learning more about becoming a member of AWG, please contact us
here.
About Summit Therapeutics plc
Summit Therapeutics is a leader in antibiotic innovation.
Summit's new mechanism antibiotics are designed to become the new
standards of care for the benefit of patients, and create value for
payors and healthcare providers. Summit is currently developing new
mechanism antibiotics for C. difficile infection and
gonorrhoea and is using its proprietary Discuva Platform to expand
its pipeline.
For more information, visit: www.summitplc.com
About The Antimicrobials Working Group
AWG was founded in 2012 with the vision of utilizing collective
power to improve the regulatory, investment, and commercial
environment for emerging infectious disease companies. Today, AWG
is comprised of nineteen antimicrobials and diagnostics companies:
Amplyx Pharmaceuticals, Aridis Pharmaceuticals, Arsanis Inc.,
Cidara Therapeutics Inc., ContraFect Corporation, Entasis
Therapeutics Inc., Iterum Therapeutics Ltd., Melinta Therapeutics
Inc., Motif Bio PLC, Nabriva Therapeutics US Inc., Paratek
Pharmaceuticals Inc., SCYNEXIS Inc., Spero Therapeutics, Inc.,
Summit Therapeutics plc, T2 Biosystems Inc., Theravance Biopharma
U.S. Inc., Viamet, Vical Incorporated, and Zavante Therapeutics
Inc.
For more information, visit:
www.antimicrobialsworkinggroup.org
About The Conafay Group
The Conafay Group, led by Stephen R.
Conafay, Principal, is a life-sciences government relations
firm based in Washington D.C. that
serves as Washington counsel and
coalition manager for AWG.
For more information, visit: www.conafaygroup.com
View original
content:http://www.prnewswire.com/news-releases/summit-therapeutics-joins-antimicrobials-working-group-300688360.html
SOURCE Antimicrobials Working Group (AWG)